CJC-1295 phase 1 human study
A 2006 trial reported that subcutaneous CJC-1295 produced sustained dose dependent increases in growth hormone and IGF-1 in healthy adults and was well tolerated.
SourceBack to search
Growth HormoneBlends
Ipamorelin / CJC-1295 (No DAC)
This blend pairs a ghrelin receptor agonist with a short acting GHRH analogue. The two pathways act together on the pituitary, producing a larger growth hormone pulse than either produces alone, which is why the combination is the most common GH stack.
- Lowest cost / mg
- $2.00/mg
- at Renova Peptides
- Vendors listed
- 62
- In stock
- 81 of 81
- listings
- COA reports
- 56
Vendor listings
Compare Ipamorelin / CJC-1295 (No DAC) prices.
Show prices as
79 listings · Ipamorelin / CJC-1295 (No DAC)
In stock10mgseen 6d ago
In stock10mgseen 3d ago
In stock5mgseen 3d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 6d ago
In stock10mgseen 5d ago
In stock10mgseen 7d ago
In stock10mgseen 6d ago
In stock20mgseen 6d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 3d ago
In stock10mgseen 4d ago
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
In stock10mgseen 7d ago
In stock10mgseen 4d ago
In stock10mgseen 6d ago
Overview
What is Ipamorelin / CJC-1295 (No DAC)?
This blend pairs a ghrelin receptor agonist with a short acting GHRH analogue. The two pathways act together on the pituitary, producing a larger growth hormone pulse than either produces alone, which is why the combination is the most common GH stack.
- GH Support
- Recovery
- Body Composition
- Sleep Quality
What the research reports
Reported research benefits
Outcomes described across the published literature and ongoing study. Read each as research context rather than a promised personal result.
- 01
Dual pathway GH stimulation
A GHRH analogue plus a ghrelin mimetic stimulates the pituitary through two routes, amplifying the pulse beyond either agent alone. Reported in research settings.
- 02
Preserved GH pulse pattern
Because both act on the pituitary rather than replacing growth hormone, the body's own pulsatile release pattern is retained. Reported in research settings.
- 03
Clean side effect profile
Ipamorelin adds little cortisol or prolactin elevation, making this pairing gentler than blends built on GHRP-2 or hexarelin. Reported in research settings.
- 04
Short drug exposure window
The no DAC form clears in about 30 minutes, so IGF-1 is not held elevated between doses the way it would be with the longer acting drug affinity complex version.
- 05
Established component data
Both components have published human pharmacokinetic studies, which is more than most blends in this directory can show. Reported in research settings.
Dosage and protocol
Dosage and protocol reference
Blend protocols use 100 to 200 mcg of each component per injection, two or three times daily, across an 8 to 12 week period. Figures describe study protocols, not a personal regimen.
- Route
- Subcutaneous injection
- Example range
- 100-200 mcg each
- Frequency
- Two to three times daily
- Timing
- Empty stomach, 30 min before food. Waking, training or bedtime.
Clinical evidence
Clinical evidence and study base
The published record, labeled by strength so you can see what is settled and what is still emerging.
Ipamorelin kinetics, 1999
A phase 1 dose escalation study in 40 human volunteers reported dose proportional kinetics, a two hour half-life and potent growth hormone stimulation. Reported in the cited paper.
SourceIpamorelin phase 2 RCT work
A 2014 randomised trial in 114 bowel resection patients found ipamorelin well tolerated but showed no significant difference against placebo on the endpoint. Reported in the cited paper.
SourceInteractions
How it pairs with other peptides
- MK-677 oral
- Stacking a third secretagogue raises IGF-1 and insulin resistance risk beyond what this pair produces.
- BPC-157 peptide
- No known negative interaction. Tissue repair and growth hormone release act on separate systems.
- Insulin therapy
- Growth hormone raises blood glucose, so glycaemic control needs review during any GH protocol.
- GHRP-2 peptide
- Duplicates the ghrelin receptor already targeted by ipamorelin, adding cortisol and prolactin effects.
Questions
Frequently asked questions.
What is Ipamorelin / CJC-1295 (No DAC)?
Ipamorelin / CJC-1295 (No DAC) is a peptide compound used in research settings. It is commonly studied for its role in growth hormone, blends, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Ipamorelin / CJC-1295 (No DAC)?
Ipamorelin / CJC-1295 (No DAC) is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Ipamorelin / CJC-1295 (No DAC) work?
Like other research peptides, Ipamorelin / CJC-1295 (No DAC) is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Ipamorelin / CJC-1295 (No DAC) for research use only?
Yes, products like Ipamorelin / CJC-1295 (No DAC) are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Ipamorelin / CJC-1295 (No DAC)?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.
